Compare
NovoCure Ltd vs UFP Technologies Inc vs iRhythm Holdings, Inc. vs Bioventus Inc.
| Latest fiscal year | NovoCure Ltd NVCR | UFP Technologies Inc UFPT | iRhythm Holdings, Inc. IRTC | Bioventus Inc. BVS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $655.35M | $602.80M | $747.14M | $568.09M |
| Revenue growth (YoY) | +8.3% | +19.5% | +26.2% | -0.9% |
| Gross margin | 74.5% | 28.3% | 70.6% | 68.3% |
| Operating margin | -23.5% | 15.3% | -7.7% | 9.5% |
| Net margin | -20.8% | 11.3% | -6.0% | 4.0% |
| Net income | -$136.23M | $68.31M | -$44.55M | $22.73M |
| EPS (Diluted) | -$1.22 | $8.75 | -$1.39 | $0.33 |
| Operating cash flow | -$49.03M | $91.91M | $80.86M | $74.67M |
| Free cash flow | -$75.68M | n/a | $34.52M | $72.11M |
| Cash & equivalents | $93.55M | $20.30M | $236.01M | $51.24M |
| Total assets | $804.33M | $655.08M | $1.02B | $683.56M |
| Total liabilities | $463.86M | $231.20M | $867.30M | $455.11M |
| Shareholders' equity | $340.47M | $423.88M | $152.75M | $184.10M |
| Return on year-end equity | -40.0% | 16.1% | -29.2% | 12.3% |
| Shares outstanding | 112.49M | 7.71M | 32.30M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | NovoCure Ltd | UFP Technologies Inc | iRhythm Holdings, Inc. | Bioventus Inc. |
|---|---|---|---|---|
| Latest | $655.35M Ended 2025-12-31 | $602.80M Ended 2025-12-31 | $747.14M Ended 2025-12-31 | $568.09M Ended 2025-12-31 |
| 1 year earlier | $605.22M Ended 2024-12-31 | $504.42M Ended 2024-12-31 | $591.84M Ended 2024-12-31 | $573.28M Ended 2024-12-31 |
| 2 years earlier | $509.34M Ended 2023-12-31 | $400.07M Ended 2023-12-31 | $492.68M Ended 2023-12-31 | $512.35M Ended 2023-12-31 |
| 3 years earlier | $537.84M Ended 2022-12-31 | $353.79M Ended 2022-12-31 | $410.92M Ended 2022-12-31 | $512.12M Ended 2022-12-31 |
| 4 years earlier | $535.03M Ended 2021-12-31 | $206.32M Ended 2021-12-31 | $322.82M Ended 2021-12-31 | $430.90M Ended 2021-12-31 |